Immune-mediated necrotizing myopathy associated with statins: history and recent developments

E Tiniakou, L Christopher-Stine - Current opinion in rheumatology, 2017 - journals.lww.com
Recent studies from different fields have revealed diverse aspects of anti-HMGCR-associated
immune-mediated necrotizing myopathy (IMNM). HMGCR IMNM is a unique autoimmune …

Intravenous immune globulin for statin-triggered autoimmune myopathy

AL Mammen, E Tiniakou - New England Journal of Medicine, 2015 - Mass Medical Soc
Although most statin-related myopathy is self-limited, in rare cases statins trigger autoimmune
myopathy, which requires control with immunosuppressive therapy. Three patients with …

More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy

E Tiniakou, I Pinal-Fernandez, TE Lloyd… - …, 2017 - academic.oup.com
Eleni TiniakouEleni Tiniakou and Iago Pinal-Fernandez contributed equally to this
study … Eleni Tiniakou and Iago Pinal-Fernandez contributed equally to this study …

Idiopathic inflammatory myopathies and malignancy: a comprehensive review

E Tiniakou, AL Mammen - Clinical reviews in allergy & immunology, 2017 - Springer
The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune
diseases (collectively known as myositis) affecting the skeletal muscles as well as other organ …

Sex-specific environmental influences on the development of autoimmune diseases

E Tiniakou, KH Costenbader, MA Kriegel - Clinical Immunology, 2013 - Elsevier
Sex differences in autoimmune diseases are evolutionarily tied to the fact that the female
immune system is confronted with intense alterations during menstrual cycles, pregnancy and …

Study of tofacitinib in refractory dermatomyositis: an open‐label pilot study of ten patients

…, JY Shin, J Albayda, E Tiniakou… - Arthritis & …, 2021 - Wiley Online Library
Objective This open‐label 12‐week study was conducted to evaluate the efficacy and safety
of tofacitinib, a JAK inhibitor, in treatment‐refractory active dermatomyositis (DM). Methods …

Use of proprotein convertase subtilisin/kexin type 9 inhibitors in statin‐associated immune‐mediated necrotizing myopathy: a case series

E Tiniakou, E Rivera, AL Mammen… - Arthritis & …, 2019 - Wiley Online Library
Objective To determine the safety of proprotein convertase subtilisin/kexin type 9 (PCSK9)
inhibitors in patients with statin‐associated anti–3‐hydroxy‐3‐methlyglutaryl coenzyme A …

Cytosolic 5′‐nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases

…, I Pinal‐Fernandez, E Tiniakou… - Arthritis care & …, 2016 - Wiley Online Library
Objective Prior investigations demonstrated that autoantibodies recognizing cytosolic 5′‐nucleotidase
1A (NT5C1A) are found in 33–76% of patients with inclusion body myositis (IBM) …

Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies

…, I Pinal-Fernandez, W Huang, J Albayda, E Tiniakou… - Neurology, 2018 - AAN Enterprises
Objective To define the clinical features of myositis patients with anti-PM/Scl-75 and/or anti-PM/Scl-100
autoantibodies at disease onset and during the course of disease and compare …

Definition of naturally processed peptides reveals convergent presentation of autoantigenic topoisomerase I epitopes in scleroderma

E Tiniakou, A Fava, ZH McMahan, T Guhr… - Arthritis & …, 2020 - Wiley Online Library
Objective Autoimmune responses to DNA topoisomerase I (topo I) are found in a subset of
scleroderma patients who are at high risk for interstitial lung disease ( ILD ) and mortality. Anti–…